Market Report Source

Overview

Introduction
Dry Overactive Bladder (dry OAB) is considered part of the overactive bladder syndrome. However, unlike wet overactive bladder (or urge urinary incontinence), it is normally only associated with urinary urgency and frequency, and not incontinence. Even so, recent studies suggest that these symptoms bother patients, with unpredictable urges disrupting daily activities and quality of life.

Scope
Quantitative treatment data from 365 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and treatment strategy for dry OAB
Influences on treatment choice and perception of current drug therapies including tolterodine, oxybutynin, darifenacin and solifenacin
Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline

Highlights
Opinion leaders often recognize the impact that urge and frequency symptoms can have on a patient, even in the absence of incontinence episodes. However, prescribing physicians in general do not all accept this readily, leading to under prescribing in this patient group.

For many years the terms urge urinary incontinence (UUI) and dry OAB have been used to describe separate syndromes with similar symptoms differentiated by the occurrence or not of incontinence. In fact is may be more suitable to consider overactive bladder as a continuum.

Although pharmacological therapy is used less frequently in dry OAB than in UUI, the products chosen are similar, based on their activity on urge and frequency via detrusor activity; occasionally a less effective product with lower side effects may be chosen for dry OAB as opposed to a stronger, but less well tolerated product for UUI.

Reasons to Purchase
Forecast product sales by understanding key aspects of dry OAB epidemiology, diagnosis and treatment
Gain a better understanding of the challenges facing current and future players in the dry OAB market
Identify physicians key concerns in dry OAB including unmet needs and the attributes that physicians believe are desirable for future treatments

Table of Contents

TABLE OF CONTENTS
OVERVIEW
This product has been designed for delivery in a slide pack format (PowerPoint).
Please select the slide pack option from the download menu at the side of the page
Introduction
Scope of this report
Research and analysis highlights
Key reasons to read this report
APPENDIX A
Research methodology
Physician Sample breakdown
Urinary Incontinence and Overactive Bladder Insight Study – Physician Questionnaire
Section One Overview of Urinary Incontinence and overactive Bladder
Epidemiology
Presentation
Diagnosis
Referral pattern
Section Two Stress Urinary Incontinence
Diagnosis and treatment of SUI
Non-pharmacological treatment
Pharmacological treatment for SUI
Section Three Overactive Bladder With Urge Symptoms and/or Incontinence
Diagnosis and treatment of UUI
Pharmacological treatment for UUI
Diagnosis and treatment of ‘dry OAB’
Pharmacological treatment for dry OAB
Section Four Mixed Stress/Urge Urinary Incontinence
Diagnosis and treatment of mixed SUI/UUI
Non-pharmacological treatment
Pharmacological treatment for mixed SUI/UUI
Section Five Interstitial Cystitis
Diagnosis and treatment of IC
Pharmacological treatment for IC
Section Six Drug Profiles
Section A: Drug influences on physicians’ choice
Section B: The general treatment of urinary incontinence and overactive bladder
Contributing experts
US
Japan
Europe
APPENDIX B
About Datamonitor
About Datamonitor Healthcare
About the CNS analysis team
Disclaimer